Company: ARVN
Filing Date: 2025-02-11
Form Type: 10-K
Source: 0001655759-25-000016
Chunk: 83

Company: ARVINAS, INC.
Filing Date: 2025-02-11
Form: 10-K
Item: Item 1
Chunk 83
---
 advantages over existing therapies and to address a broad range of targets, including historically undruggable proteins. We are currently developing PROTAC degraders to address targets within oncology, hematology, and neuroscience, and we see applicability in other therapeutic areas as well. The key elements of our strategy are to: 

•Focus on near-term patient impact and advance clinical development of our lead PROTAC program, vepdegestrant, which is designed to degrade the ER, that is well-understood to be a biological pathway driving breast cancer. Vepdegestrant is the first PROTAC ER degrader to enter Phase 3 clinical trials and we have characterized its degradation and potent anti-tumor effects alone and in combination with CDK inhibitors across preclinical disease models. In addition, ER degradation is being evaluated in clinical samples from our ongoing clinical trials, including VERITAC AND TACTIVE-N. Vepdegestrant is our one product candidate in Phase 3 clinical development, and we are planning for multiple potential launches with vepdegestrant as both a monotherapy and in combination. 

•Progress our therapeutic footprint beyond ER by furthering the programs in our oncology (including hematology) and neuroscience portfolios. We are focused on creating potential therapies for patients with hematological and neurological diseases, including our product candidates, ARV-393 and ARV-102, which are currently in Phase 1 clinical development. We believe that favorable clinical trial results with these initial hematology and neuroscience programs will validate the broader therapeutic potential of our PROTAC technology. In addition, ARV-393 degrades the historically "undruggable" BCL6 with potential to impact and provide oral therapeutic alternatives to patients with NHL, while ARV-102 degrades LRRK2 with potential to impact patients with PSP or PD.

•Utilize our PROTAC Discovery Engine platform to address historically undruggable and difficult-to-drug targets. We are applying our platform to develop treatments for patients with diseases associated with historically undruggable targets. Our platform enables us to build PROTAC targeted protein degraders with the potential to degrade these proteins through the cell’s natural protein degradation process using any available binding site, including low-affinity active binding sites or non-functional binding sites, bringing biological utility to ligands that would 

10

otherwise be inactive. We also believe that many “difficult-to-drug” targets, where prior approaches are inadequate, will also provide opportunities to apply our PROTAC technology.

•Develop